protein

CHOLESTEROL

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about CHOLESTEROL: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1850Connections

22Hypotheses

2Analyses

50Outgoing

50Incoming

6Experiments

6Debates

No summary available yet.

View on Wiki →

No AI portrait yet

🔬 Protein Info

Gene Symbol	CHOLESTEROL
Associated Diseases	ALZHEIMER'S DISEASE, COGNITIVE DECLINE, DEPRESSION, GLUTAMATE, IMMUNE RESPONSE, LYSOSOMAL DYSFUNCTION
Known Drugs/Compounds	DEXAMETHASONE, LUTEOLIN, RAPAMYCIN
KG Connections	299 knowledge graph edges
Databases	GeneCards UniProt NCBI Gene HPA STRING

Pathway Diagram

graph TD
    CHOLESTEROL["CHOLESTEROL"] -->|"correlated with"| DEPRESSION["DEPRESSION"]
    style DEPRESSION fill:#1a2a3a,stroke:#ef5350,stroke-width:1px,color:#fff
    CHOLESTEROL["CHOLESTEROL"] -->|"triggers"| inflammasome_activation["inflammasome activation"]
    style inflammasome_activation fill:#1a2a3a,stroke:#ffd54f,stroke-width:1px,color:#fff
    CHOLESTEROL["CHOLESTEROL"] -->|"destabilizes"| LDLR["LDLR"]
    style LDLR fill:#1a2a3a,stroke:#ce93d8,stroke-width:1px,color:#fff
    CHOLESTEROL["CHOLESTEROL"] -->|"activates"| PARKINSON_S_DISEASE["PARKINSON'S DISEASE"]
    style PARKINSON_S_DISEASE fill:#1a2a3a,stroke:#ef5350,stroke-width:1px,color:#fff
    CHOLESTEROL["CHOLESTEROL"] -->|"interacts"| PROTEIN_AGGREGATION["PROTEIN AGGREGATION"]
    style PROTEIN_AGGREGATION fill:#1a2a3a,stroke:#ffd54f,stroke-width:1px,color:#fff
    CHOLESTEROL["CHOLESTEROL"] -->|"regulates"| BACE1["BACE1"]
    style BACE1 fill:#1a2a3a,stroke:#ce93d8,stroke-width:1px,color:#fff
    CHOLESTEROL["CHOLESTEROL"] -->|"stabilizes"| SYNAPTIC_PLASTICITY["SYNAPTIC PLASTICITY"]
    style SYNAPTIC_PLASTICITY fill:#1a2a3a,stroke:#ffd54f,stroke-width:1px,color:#fff
    APOE["APOE"] -->|"transports"| CHOLESTEROL["CHOLESTEROL"]
    style APOE fill:#1a2a3a,stroke:#ce93d8,stroke-width:1px,color:#fff
    CYP46A1["CYP46A1"] -->|"metabolizes"| CHOLESTEROL["CHOLESTEROL"]
    style CYP46A1 fill:#1a2a3a,stroke:#ce93d8,stroke-width:1px,color:#fff
    LRP1["LRP1"] -->|"transports"| CHOLESTEROL["CHOLESTEROL"]
    style LRP1 fill:#1a2a3a,stroke:#ce93d8,stroke-width:1px,color:#fff
    CA1["CA1"] -->|"regulates"| CHOLESTEROL["CHOLESTEROL"]
    style CA1 fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#fff
    DEXAMETHASONE["DEXAMETHASONE"] -->|"activates"| CHOLESTEROL["CHOLESTEROL"]
    style DEXAMETHASONE fill:#1a2a3a,stroke:#81c784,stroke-width:1px,color:#fff
    style CHOLESTEROL fill:#006494,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0,font-weight:bold

Outgoing (398)

Target	Relation	Type	Str
Astrocyte	regulates	cell_type	0.80
inflammatory escalation	promotes	process	0.80
neuronal accumulation	causes	process	0.70
oligodendrocyte myelin maintenance	activates	process	0.70
amyloid pathology	regulates	mechanism	0.70
BDNF	destabilizes	gene	0.70
ASTROCYTE	produces	cell_type	0.70
DOPAMINE	inhibits	phenotype	0.70
APOE	protects_against	gene	0.70
APOE	produces	gene	0.70
OPTN	inhibits	protein	0.70
DEMENTIA	interacts_with	disease	0.70
CEREBELLUM	associated_with	brain_region	0.70
PINK1	activates	protein	0.70
LDLR	destabilizes	gene	0.70
LDLR	causes	gene	0.70
MEMORY LOSS	activates	phenotype	0.70
MEMORY LOSS	inhibits	phenotype	0.70
BACE1	regulates	gene	0.70
SYNAPTIC PLASTICITY	stabilizes	phenotype	0.70
PROTEIN AGGREGATION	interacts_with	phenotype	0.70
PARKINSON'S DISEASE	activates	disease	0.70
SYNAPTIC PLASTICITY	inhibits	phenotype	0.70
LUTEOLIN	inhibits	drug	0.65
INSULIN RESISTANCE	treats	phenotype	0.65
OXIDATIVE STRESS	transports	phenotype	0.65
HMGCR	destabilizes	gene	0.65
AUTOPHAGY	protects_against	phenotype	0.65
NEURONS	causes	cell_type	0.65
NEURONS	treats	cell_type	0.65
LDLR	treats	gene	0.65
MULTIPLE SCLEROSIS	causes	disease	0.65
CYP46A1	encodes	gene	0.65
NLRP3 INFLAMMASOME	regulates	pathway	0.65
NEUROINFLAMMATION	exacerbates	phenotype	0.65
HEDGEHOG SIGNALING	inhibits	pathway	0.65
WHITE MATTER	causes	brain_region	0.65
CEREBRAL CORTEX	interacts_with	brain_region	0.65
BDNF	protects_against	gene	0.65
DEMYELINATION	treats	phenotype	0.65
CORTEX	interacts_with	brain_region	0.65
ALZHEIMER'S DISEASE	increases_risk	disease	0.65
LRRK2	regulates	gene	0.65
LRRK2	activates	gene	0.65
WHITE MATTER	activates	brain_region	0.65
NICOTINAMIDE	causes	drug	0.65
PYROPTOSIS	causes	phenotype	0.65
PYROPTOSIS	regulates	phenotype	0.65
SENESCENCE	causes	phenotype	0.65
NEURONS	produces	cell_type	0.65

Incoming (1452)

Source	Relation	Type	Str
CANCER	therapeutic_target	gene	1.00
AUTOPHAGY	activates	gene	1.00
MIRNAS	regulates	gene	1.00
Als	associated_with	disease	1.00
Inflammation	regulates	disease	1.00
Inflammation	activates	disease	1.00
INFLAMMATION	activates	gene	1.00
Cancer	therapeutic_target	disease	1.00
Als	activates	disease	1.00
APOE	activates	gene	1.00
Als	regulates	disease	1.00
Cardiovascular	regulates	disease	1.00
Cancer	regulates	disease	1.00
Als	inhibits	disease	1.00
APOE	inhibits	gene	1.00
GENES	regulates	gene	1.00
Atherosclerosis	regulates	disease	1.00
CANCER	regulates	gene	1.00
Atherosclerosis	inhibits	disease	1.00
ALZHEIMER'S DISEASE	activates	gene	1.00
Inflammation	therapeutic_target	disease	1.00
Alzheimer	therapeutic_target	disease	1.00
APOE	associated_with	gene	1.00
MICRORNAS	regulates	gene	1.00
Diabetes	activates	disease	1.00
AKT	activates	gene	1.00
Atherosclerosis	associated_with	disease	0.95
36385529	aberrantly deposited in	paper	0.90
SREBF2	regulates	gene	0.90
24155031	binds	paper	0.90
Inflammation	inhibits	disease	0.90
INFLAMMATION	inhibits	gene	0.90
LDL	activates	gene	0.90
EGFR	activates	gene	0.90
APOE4	activates	gene	0.90
SREBP2	activates	gene	0.90
INFLAMMATION	therapeutic_target	gene	0.90
Als	therapeutic_target	disease	0.90
Atherosclerosis	activates	disease	0.90
Als	biomarker_for	disease	0.90
Alzheimer	regulates	disease	0.90
AUTOPHAGY	regulates	gene	0.90
AKT	inhibits	gene	0.90
Aging	associated_with	disease	0.90
Tumor	inhibits	disease	0.90
Alzheimer	activates	disease	0.90
LDL	inhibits	gene	0.90
ALZHEIMER	activates	gene	0.90
ALZHEIMER'S DISEASE	therapeutic_target	gene	0.90
GENES	activates	gene	0.90

Targeting Hypotheses (22)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
CYP46A1-Mediated Cholesterol Reduction Prevents eIF2α-Driven	0.819	neurodegeneration	Lipid raft composition changes in synapt
Selective LXRβ agonists restore ABCA1/ABCG1 expression and A	0.763	neuroscience	APOE4-driven lipid metabolism dysregulat
APOE4 astrocytes exhibit impaired cholesterol efflux via ABC	0.758	neuroscience	APOE4-driven lipid metabolism dysregulat
APOE4-driven lysosome-to-ER cholesterol transport failure re	0.741	molecular-biology	Does APOE4's reduced lipid-binding direc
H3: APOE4 Impairs Cholesterol Trafficking, Triggering Astroc	0.720	neurodegeneration	Do APOE4-driven senescent astrocytes cau

Membrane Cholesterol Gradient Modulators	0.708	neurodegeneration	Lipid raft composition changes in synapt
APOE4 hypolipidation and ABCA1 mistrafficking impair cholest	0.694	molecular-biology	Does APOE4's reduced lipid-binding direc
TREM2 R47H Metabolic Lock-in at Cholesterol Ester Accumulati	0.670	neuroimmunology	What is the temporal sequence of TREM2 s
LXRβ-Selective Agonism to Simultaneously Enhance APOE Lipida	0.668	lipidomics	Lipid metabolism dysregulation in Alzhei
TREM2-Mediated Cholesterol Dysregulation in Microglial Senes	0.666	neurodegeneration	Gene expression changes in aging mouse b
Cholesterol-CRISPR Convergence Therapy for Neurodegeneration	0.622	neurodegeneration	CRISPR-based therapeutic approaches for
APOE4 preferentially signals through LRP1 over LDLR, alterin	0.610	neuroscience	APOE4-driven lipid metabolism dysregulat
CYP46A1 Activation as a Therapeutic Strategy to Restore Neur	0.550	lipidomics	Lipid metabolism dysregulation in Alzhei
ApoE4-Mediated Failure of Cholesterol Efflux as Memory Maint	0.515	neuroinflammation	What specific astrocyte-derived factors
APOE4 astrocytes fail to supply sufficient cholesterol to pa	0.500	neuroscience	APOE4-driven lipid metabolism dysregulat
Cholesterol Depletion-Targeting Nanobody Vectors	0.455	molecular-biology	Can nanobodies achieve selective membran
APOE4 alters the accessible-cholesterol threshold sensed by	0.420	molecular-biology	Does APOE4's reduced lipid-binding direc
LXRα-Selective Agonism to Enhance Hepatic APOE Secretion and	0.380	lipidomics	Lipid metabolism dysregulation in Alzhei
ABCA1 Upregulation via LXRβ Agonism to Enhance Cholesterol E	0.380	lipidomics	Lipid metabolism dysregulation in Alzhei
LDLR-Mediated Reverse Cholesterol Transport Modulation for C	0.380	neuropharmacology	What is the actual quantitative contribu
Poorly lipidated APOE4 particles are preferentially routed t	0.340	molecular-biology	Does APOE4's reduced lipid-binding direc
Cholesterol-Sphingolipid Ratio Modulators as Synaptic Rescue	0.000	-	Lipid raft composition changes in synapt

Mentioning Analyses (2)

Scientific analyses that reference this entity

Is myelin loss in AD causal or an adaptive response to neuronal damage?

neurodegeneration | 2026-04-11 | 0 hypotheses

Lipid raft composition changes in synaptic neurodegeneration

neurodegeneration | 2026-04-01 | 22 hypotheses Top: 0.852

Experiments (6)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Unilateral ureteral obstruction model for hyperoside treatment	validation	chronic kidney disease	0.900	0.00	unilateral ureteral obstructio	proposed	N/A
Folic acid-induced nephropathy model for hyperoside renoprotection	validation	chronic kidney disease	0.900	0.00	folic acid-induced nephropathy	proposed	N/A
Hyperoside-ACAT1 direct binding interaction studies	exploratory	chronic kidney disease	0.850	0.00	in vitro protein-ligand bindin	proposed	N/A
L-carnitine rescue experiments in metabolic pathway	exploratory	chronic kidney disease	0.800	0.00	ACAT1 knockdown with L-carniti	proposed	N/A
Acat1 knockdown functional validation experiment	exploratory	chronic kidney disease	0.800	0.00	Acat1 knockdown cells/tissues	proposed	N/A
Metal Ion Homeostasis Dysregulation in Alzheimer's Disease	validation	Alzheimer's Disease	0.400	0.50	human	proposed	$2,730,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Metabolic orchestration of cell death by AMPK-mediated phosphorylation of RIPK1. [PMID:37384704]	Zhang T, Xu D, Trefts E, Lv M, Inuzuka H	Science	2023	1
TREM2, microglia, and Alzheimer's disease. [PMID:33516818]	Qin Q, Teng Z, Liu C, Li Q, Yin Y, Tang	Mech Ageing Dev	2021	1
Metformin Improves Mitochondrial Respiratory Activity through Activation of AMPK [PMID:31693892]	Wang Y, An H, Liu T, Qin C, Sesaki H, Gu	Cell Rep	2019	1
TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. [PMID:28802038]	Ulland TK, Song WM, Huang SC, Ulrich JD,	Cell	2017	1
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025	0
The cholesterol 24-hydroxylase CYP46A1 promotes α-synuclein pathology in Parkins [PMID:39964974]	Dai L, Wang J, Meng L, Zhang X, Xiao T,	PLoS biology	2025	0
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025	0
Development of Injectable Thermosensitive Nanocomposite Hydrogel for Ratiometric [PMID:38456789]	["Zhu J", "Wei R", "Hu G", "Wang H", "Wa	Small (Weinheim an der Bergstr	2024	0
The expanding world of neuroscience. [PMID:39423798]	Unknown	Cell	2024	0
RNA-Independent Regulatory Functions of lncRNA in Complex Disease. [PMID:39123456]	["Kafida M", "Karela M", "Giakountis A"]	Cancers	2024	0
Raccoon eyes [PMID:35789012]	Ning Junjie	Journal of Paediatrics and Chi	2023	0
Isolated Trapeziometacarpal Joint Dislocation With Five Years of Follow-up: A Ca [PMID:36891023]	["Missaoui Z", "Moussa M", "Boushnak M",	Cureus	2023	0
Exploring factors associated with preferences for human papillomavirus (HPV) sel [PMID:37234567]	["Xiong S", "Ghebre R", "Kulasingam S",	Preventive medicine reports	2023	0
Patient's Knowledge and Perception of Endodontics Treatment: An Observational St [PMID:37654321]	["Manasa N", "Naik K", "Singh M", "Moiz	Journal of pharmacy & bioallie	2023	0
Photosynthetic acclimation to changing environments. [PMID:36892145]	["Gjindali A", "Johnson G"]	Biochemical Society transactio	2023	0
Antiviral, immunomodulatory, and anticoagulant effects of quercetin and its deri [PMID:34567823]	["Manjunath S", "Thimmulappa R"]	Journal of pharmaceutical anal	2022	0
ATAD3A oligomerization promotes neuropathology and cognitive deficits in Alzheim [PMID:35236834]	Zhao Y, Hu D, Wang R, Sun X, Ropelewski	Nature communications	2022	0
Comparative study of haemodynamic effects of intravenous ketamine-fentanyl and p [PMID:35102948]	["Okeyemi A", "Suleiman A", "Oyedepo O",	The Nigerian postgraduate medi	2022	0
TREM2, microglia, and Alzheimer's disease. [PMID:33516818]	Qin Q, Teng Z, Liu C, Li Q, Yin Y et al.	Mech Ageing Dev	2021	0
Ambulatory Care Sensitive Conditions in Pediatrics: Time for a Reassessment. [PMID:34215678]	Sam Lu	Pediatrics	2021	0

Debates (6)

Multi-agent debates referencing this entity

Extended debate: CYP46A1 Overexpression Gene Therapy

closed · Rounds: 6 · Score: 0.95 · 2026-04-27

Hypothesis debate: Membrane Cholesterol Gradient Modulators

closed · Rounds: 4 · Score: 0.50 · 2026-04-27

Hypothesis debate: Selective Acid Sphingomyelinase Modulation Therapy

closed · Rounds: 4 · Score: 0.40 · 2026-04-27

Hypothesis debate: CYP46A1 Overexpression Gene Therapy

closed · Rounds: 4 · Score: 0.40 · 2026-04-27

The debate raised conflicting views on whether myelin restoration would be benef

closed · Rounds: 4 · Score: 1.00 · 2026-04-20

Investigate how lipid raft composition (cholesterol metabolism, sphingolipids) c

closed · Rounds: 5 · Score: 0.93 · 2026-04-11

Related Research

Hypotheses and analyses mentioning CHOLESTEROL in their description or question text

Membrane Cholesterol Gradient Modulators

Score: 0.708 · neurodegeneration · 2026-04-02

## Mechanistic Overview Membrane Cholesterol Gradient Modulators starts from the claim that modulating ABCA1/LDLR/SREBF2

APOE4 hypolipidation and ABCA1 mistrafficking impair cholesterol efflux and seco

Score: 0.694 · molecular-biology · 2026-04-24

A plausible upstream submechanism is that lipid-poor APOE4 disrupts ABCA1 trafficking, likely via ARF6-associated endoso

TREM2 R47H Metabolic Lock-in at Cholesterol Ester Accumulation

Score: 0.670 · neuroimmunology · 2026-04-15

## Mechanistic Overview TREM2 R47H Metabolic Lock-in at Cholesterol Ester Accumulation starts from the claim that modula

LXRβ-Selective Agonism to Simultaneously Enhance APOE Lipidation and Reduce Micr

Score: 0.668 · lipidomics · 2026-04-25

LXRβ-selective agonism represents a targeted strategy to simultaneously enhance APOE lipidation and reduce microglial ch

TREM2-Mediated Cholesterol Dysregulation in Microglial Senescence

Score: 0.666 · neurodegeneration · 2026-04-07

## Mechanistic Overview TREM2-Mediated Cholesterol Dysregulation in Microglial Senescence starts from the claim that mod

Cholesterol-CRISPR Convergence Therapy for Neurodegeneration

Score: 0.622 · neurodegeneration · 2026-04-02

## Mechanistic Overview Cholesterol-CRISPR Convergence Therapy for Neurodegeneration starts from the claim that modulati

APOE4 preferentially signals through LRP1 over LDLR, altering endosomal choleste

Score: 0.610 · neuroscience · 2026-04-22

**Molecular Mechanism and Rationale** The apolipoprotein E4 (APOE4) isoform, present in approximately 25% of the popula

CYP46A1 Activation as a Therapeutic Strategy to Restore Neuronal Cholesterol Eff

Score: 0.550 · lipidomics · 2026-04-25

CYP46A1 Activation as a Therapeutic Strategy to Restore Neuronal Cholesterol Efflux and Reduce Aβ Production

ApoE4-Mediated Failure of Cholesterol Efflux as Memory Maintenance Mechanism

Score: 0.515 · neuroinflammation · 2026-04-26

Incomplete hypothesis (truncated). ApoE4 isoform from astrocytes fails to mediate proper cholesterol efflux from microgl

APOE4 astrocytes fail to supply sufficient cholesterol to parvalbumin interneuro

Score: 0.500 · neuroscience · 2026-04-22

## Mechanistic Overview APOE4 astrocytes fail to supply sufficient cholesterol to parvalbumin interneurons, causing pres

Cholesterol Depletion-Targeting Nanobody Vectors

Score: 0.455 · molecular-biology · 2026-04-27

Nanobodies designed to preferentially penetrate cholesterol-depleted membranes could selectively target tau-containing v

APOE4 alters the accessible-cholesterol threshold sensed by SCAP through ER memb

Score: 0.420 · molecular-biology · 2026-04-24

A more conjectural model is that APOE4-driven lipid remodeling changes ER membrane organization so that SCAP perceives c

LXRα-Selective Agonism to Enhance Hepatic APOE Secretion and Peripheral Choleste

Score: 0.380 · lipidomics · 2026-04-27

This hypothesis proposes that selective activation of LXRα (NR1H3) represents a superior therapeutic approach for addres

ABCA1 Upregulation via LXRβ Agonism to Enhance Cholesterol Efflux and Prevent Ne

Score: 0.380 · lipidomics · 2026-04-26

This hypothesis proposes that selective LXRβ agonism primarily functions through transcriptional upregulation of ABCA1 (

LDLR-Mediated Reverse Cholesterol Transport Modulation for CNS Drug Delivery

Score: 0.380 · neuropharmacology · 2026-04-27

The LDLR-Mediated Reverse Cholesterol Transport Modulation strategy proposes that CNS drug delivery can be enhanced by h